CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Operating activities
Net loss	$ (56,418)	$ (55,193)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1,710	2,001
Amortization and accretion on investment securities, net	(2,509)	(1,897)
Future royalty payment contingency interest accretion	2,546	2,350
Share-based compensation	21,393	25,371
loss on disposal of property and equipment	34	1,352
Loss on impairment of long-lived assets	4,513
Amortization of right-of-use assets	4,414	4,152
Deferred income taxes	(7,573)	3,207
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	(966)	(689)
Prepaid clinical and development services	1,965	(526)
Other prepaid and current assets	7,399	(3,921)
Right-of-use lease assets	(707)	(314)
Other assets	411	(1,233)
Accounts payable	750	6
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	1,468	(7,095)
Deferred revenue		(216)
Operating lease liabilities	661	(3,001)
Unrecognized tax benefits	9,906	1,102
Other long-term liabilities	(532)	7,547
Net cash used in operating activities	(11,535)	(26,997)
Investing activities
Purchases of property and equipment	(332)	(2,488)
Purchases of marketable securities	(140,743)	(134,534)
Maturities of marketable securities	139,813	31,435
Purchase of derivative	(2,292)
Sale of short-term investments and marketable securities	15,838	71,377
Proceeds from the sale of property and equipment		1,513
Net cash provided by (used in) investing activities	12,284	(32,697)
Financing activities
Ordinary share repurchases	(445)	(197,051)
Proceeds from the sale of ordinary shares	99
Proceeds from ESPP purchases	508	618
Repurchase of shares to satisfy tax withholding	(2,659)	(2,500)
Net cash used in financing activities	(2,497)	(198,933)
Net decrease in cash, cash equivalents, and restricted cash	(1,748)	(258,627)
Cash, cash equivalents, and restricted cash at beginning of period	40,381	299,008
Cash, cash equivalents, and restricted cash at end of period	38,633	40,381
Supplemental disclosure of cash flow information
Cash paid for income taxes, net	$ 109	24
Supplemental disclosure of non-cash activities
Recognition of tenant improvement allowance assigned to sublease		$ 6,490